Characteristic Genotypes of Vascular Endothelial Growth Factor are Susceptible to Ascites in Patients with Cirrhosis

Abstract

This study was designed to investigate whether different vascular endothelial growth factor (VEGF) genotypes are associated with ascites formation in cirrhotic patients. Seventy cirrhotic patients were included in the study: 25 cirrhotic patients with ascites and 45 cirrhotic patients without ascites. Patient characteristics were investigated and compared between the two groups. With regard to VEGF genotype, 42 patients were C/C and 28 patients were T/T or C/T. The genotypes T/T or C/T were observed in 23 cases (51%) among the non-ascites group, but in only five cases (20%) among the ascites group. Serum levels of albumin and creatinine, and the VEGF genotypes were significantly different between the two groups. Multiple regression analysis showed that serum levels of creatinine and the VEGF genotypes were significantly correlated with ascites formation. Thus, it can be concluded that VEGF genotyping might be a valuable susceptibility marker for ascites formation in cirrhotic patients.

Keywords

Cirrhosis Patients with ascites Vascular endothelial growth factor (VEGF)Genotype

References

Ginés

Quintero

Arroyo

: Compensated cirrhosis: Natural history and prognostic factors. Hepatology 1987; 7: 122–128.

Caly

Strauss

: A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 353–358.

Moreau

Delègue

Pessione

: Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int 2004; 24: 457–464.

Moore

Aithal

: Guidelines on the management of ascites in cirrhosis. Gut 2006; 55 (suppl 6): vi1–vi12.

Ackerman

: Ascites in nephrotic syndrome. Incidence, patients’ characteristics, and complications. J Clin Gastroenterol 1996; 22: 31–34.

Nagy

Masse

Herzberg

: Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995; 55: 360–368.

Kraft

Weindel

Ochs

: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999; 85: 178–187.

Renner

Kotschan

Hoffmann

: A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37: 443–448.

Akiyoshi

Sata

Suzuki

: Serum levels of vascular endothelial growth factor in various liver diseases. Dig Dis Sci 1998; 43: 41–45.

10.

Taniguchi

Sakisaka

Matsuo

: Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 2001; 49: 121–130.

11.

Suzuki

Mori

Kawaguchi

: Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. Int J Oncol 1999; 14: 1087–1090.

12.

Qin

Tang

: The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385–392.

13.

Poon

Lau

: High serum levels of vascular endothelial growth factor predict poor response to transarterial chemo-embolization in hepatocellular carcinoma: A prospective study. Oncol Rep 2004; 11: 1077–1084.

14.

Torimura

Sata

Ueno

: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998; 29: 986–991.

15.

Gerbes

: The patient with refractory ascites. Best Pract Res Clin Gastroenterol 2007; 21: 551–560.

16.

Pérez-Ruiz

Ros

Ruiz

M Morales

: Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: Regulation by cytokines and bacterial lipopolysaccharide. Hepatology 1999; 29: 1057–1063.

17.

Cejudo-Martin

Ros

Navasa

: Increased production of vascular endothelial growth factor in peritoneal macrophages of cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2001; 34: 487–493.

18.

Ikuhashi

Yoshida

Kennedy

: Vascular endothelial growth factor +936 C/T polymorphism is associated with an increased risk of endometriosis in a Japanese population. Acta Obstet Gynecol Scand 2007; 86: 1352–1358.

19.

Osusky

Hallahan

: The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7: 225–233.

20.

Ueda

Yamagishi

Ikeya

: VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo. Anticancer Res 2004; 24: 3009–3017.

21.

Zhang

Z-L

Liu

Z-S

Sun

: Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World J Gastroenterol 2005; 11: 216–220.